8-K: Gilead Q3 2025 Results: Strong Portfolio Growth, Patent Win

Gilead Sciences reports a 3% increase in Q3 2025 total revenues to $7.8 billion, driven by robust HIV and Livdelzi sales, and an extended Biktarvy patent exclusivity.

Summary

• Total Q3 2025 revenues increased 3% year-over-year to $7.8 billion.
• Total product sales decreased 2% to $7.3 billion, primarily due to lower Veklury and Cell Therapy sales.
• Total product sales excluding Veklury increased 4% to $7.1 billion.
• Diluted earnings per share (EPS) was $2.43 in Q3 2025, compared to $1.00 in Q3 2024, primarily due to the non-recurrence of a prior year $1.75 billion in-process research and development (IPR&D) impairment charge.
• Non-GAAP diluted EPS increased 22% to $2.47 in Q3 2025, compared to $2.02 in Q3 2024.
• HIV product sales increased 4% to $5.3 billion, with Biktarvy sales up 6% to $3.7 billion and Descovy sales up 20% to $701 million.
• Liver Disease portfolio sales increased 12% to $819 million, driven by higher demand for Livdelzi.
• Veklury sales decreased 60% to $277 million, primarily due to lower rates of COVID-19-related hospitalizations.
• Cell Therapy product sales decreased 11% to $432 million, reflecting ongoing competitive headwinds, with Yescarta sales down 10% to $349 million and Tecartus sales down 15% to $83 million.
• Trodelvy sales increased 7% to $357 million.
• Gilead generated $4.1 billion in operating cash flow during Q3 2025.
• The company paid dividends of $1.0 billion and repurchased $435 million of common stock during Q3 2025.
• Full-year 2025 guidance for product sales was updated to $28.4 billion $28.7 billion (previously $28.3 billion $28.7 billion).
• Full-year 2025 guidance for diluted EPS was updated to $6.65 $6.85 (previously $5.85 $6.15).
• Full-year 2025 guidance for non-GAAP diluted EPS was updated to $8.05 $8.25 (previously $7.95 $8.25).

Sentiment

Score: 8

Explanation: The filing indicates strong financial performance with increased revenues (excluding Veklury), significant EPS growth, and raised full-year guidance. The extension of Biktarvy's patent exclusivity is a major positive, securing a key revenue stream for an extended period. While Cell Therapy sales faced headwinds, the overall pipeline momentum, strategic investments, and positive rating outlook contribute to a very favorable sentiment.

Positives

• Total revenues increased 3% year-over-year to $7.8 billion.
• Product sales excluding Veklury increased 4% to $7.1 billion, indicating strong performance in core franchises.
• Diluted EPS significantly increased to $2.43 from $1.00 in Q3 2024, benefiting from the non-recurrence of a $1.75 billion IPR&D impairment charge.
• Non-GAAP diluted EPS rose 22% to $2.47, demonstrating strong underlying profitability.
• HIV product sales grew 4% to $5.3 billion, driven by robust performance from Biktarvy (up 6% to $3.7 billion) and Descovy (up 20% to $701 million).
• Liver Disease portfolio sales increased 12% to $819 million, led by higher demand for Livdelzi.
• Trodelvy sales increased 7% to $357 million, showing continued growth in oncology.
• Biktarvy patent litigation settlement extends U.S. exclusivity to April 1, 2036, more than two years later than previous projections (December 2033), securing a key revenue stream for longer.
• Yeztugo (lenacapavir) received a strong recommendation for HIV pre-exposure prophylaxis (PrEP) in new U.S. CDC guidelines and European Commission marketing authorization.
• A partnership with the U.S. State Department and PEPFAR aims to deliver lenacapavir for HIV PrEP to up to two million people over three years.
• Moodys affirmed Gilead's A3 senior unsecured rating and upgraded the company's outlook to positive from stable, citing momentum in the product pipeline.
• Gilead announced ground-breaking on a new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City, California, as part of a planned $32 billion investment in the U.S. through 2030.
• Full-year 2025 guidance for product sales, diluted EPS, and non-GAAP diluted EPS was raised, indicating increased confidence in future performance.

Negatives

• Total product sales decreased 2% to $7.3 billion compared to the same period in 2024.
• Veklury sales decreased 60% to $277 million, primarily driven by lower rates of COVID-19-related hospitalizations.
• Cell Therapy product sales decreased 11% to $432 million, reflecting ongoing competitive headwinds.
• Yescarta sales decreased 10% to $349 million, primarily driven by lower demand.
• Tecartus sales decreased 15% to $83 million, primarily reflecting lower demand.
• Cash, cash equivalents and marketable debt securities decreased to $9.4 billion as of September 30, 2025, from $10.0 billion as of December 31, 2024.

Risks

• Ability to achieve full-year 2025 financial guidance, including as a result of the uncertainty of the amount and timing of Veklury revenues, the impact of the Inflation Reduction Act, changes in U.S. regulatory or legislative policies, and changes in U.S. trade policies, including tariffs.
• Ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy.
• Ability to accelerate or sustain revenues for its virology, oncology, and other programs.
• Ability to realize the potential benefits of acquisitions, collaborations, or licensing arrangements, including the acquisitions of Interius, and the arrangements with Pregene and PEPFAR.
• Risk that Gilead's U.S. manufacturing and R&D investment may not achieve their intended benefits.
• Patent protection and estimated loss of exclusivity for products and product candidates, including with respect to Biktarvy.
• Ability to initiate, progress, or complete clinical trials within currently anticipated timeframes or at all.
• Possibility of unfavorable results from ongoing and additional clinical trials, including those involving Trodelvy, domvanalimab, and zimberelimab (such as the ASCENT-03, and EDGE-Gastric studies).
• Risk that safety and efficacy data from clinical trials may not warrant further development of product candidates or the product candidates of strategic partners.
• Ability to resolve the issues cited by the FDA in pending clinical holds to the satisfaction of the FDA and the risk that FDA may not remove such clinical holds, in whole or in part, in a timely manner or at all.
• Ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines.
• Ability to receive or maintain regulatory approvals in a timely manner or at all, including for additional approvals for lenacapavir for HIV PrEP.
• Risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority.
• Ability to successfully commercialize its products.
• Risk of potential disruptions to the manufacturing and supply chain of products.
• Pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts.
• A larger than anticipated shift in payer mix to more highly discounted payer segments.
• Market share and price erosion caused by the introduction of generic versions of Gilead products.
• Risk that physicians and patients may not see advantages of Gilead's products over other therapies and may therefore be reluctant to prescribe the products, including Yeztugo/Yeytuo.
• Ability to effectively manage the access strategy relating to lenacapavir for HIV PrEP, subject to necessary regulatory approvals.

Future Outlook

Gilead updated its full-year 2025 guidance, raising the low end of product sales to $28.4 billion $28.7 billion and increasing diluted EPS to $6.65 $6.85 and non-GAAP diluted EPS to $8.05 $8.25. The company anticipates multiple potential product launches in 2026 and highlights its strongest clinical pipeline in history, with no major loss of exclusivity expected until 2036.

Management Comments

• "We continue to deliver on Gilead's robust portfolio with a strong start for Yeztugo, rapidly growing uptake of Biktarvy, Descovy and Livdelzi, and positive data for Trodelvy in 1L metastatic triple negative breast cancer."
• "With multiple potential product launches in 2026, the strongest clinical pipeline in Gilead's history, and no major loss of exclusivity expected until 2036, we are well-positioned to drive positive impact for patients and continued growth of our business."

Industry Context

Gilead's strong performance in HIV, particularly with Biktarvy and Descovy, demonstrates continued market leadership in a highly competitive therapeutic area. The decline in Veklury sales reflects the broader trend of decreasing COVID-19 related hospitalizations, impacting companies that benefited significantly from the pandemic. The challenges in Cell Therapy sales, with declines in Yescarta and Tecartus, indicate increasing competitive pressures in the CAR T-cell therapy space. The extended patent exclusivity for Biktarvy provides a significant competitive advantage and long-term revenue stability, differentiating Gilead from peers facing earlier patent cliffs. The strategic investments in R&D and manufacturing, coupled with pipeline advancements, position Gilead for future growth in oncology and other therapeutic areas, aligning with the industry's focus on innovation and diversification.

Comparison to Industry Standards

• The extension of Biktarvy's U.S. patent exclusivity to April 1, 2036, significantly surpasses typical patent lifespans for blockbuster drugs, providing a competitive moat that many pharmaceutical companies struggle to maintain. For example, AbbVie's Humira faced biosimilar competition after a long run, and many other drugs face generic entry much earlier than 2036.
• The 60% decrease in Veklury sales highlights the volatility of pandemic-related revenue streams, a common trend seen across companies that developed COVID-19 treatments or vaccines, such as Pfizer's Comirnaty and Paxlovid, which have also seen declining sales post-peak.
• The 11% decline in Cell Therapy sales (Yescarta down 10%, Tecartus down 15%) suggests increasing competition in the CAR T-cell market, where companies like Novartis (Kymriah) and Bristol Myers Squibb (Abecma, Breyanzi) are also vying for market share. This indicates a more challenging environment than in earlier stages of CAR T adoption.
• The positive outlook from Moody's, upgrading to "positive" from "stable" for its A3 senior unsecured rating, reflects a strong financial position and pipeline momentum, which is a favorable assessment compared to many peers in the biopharmaceutical sector that may face rating pressures due to R&D costs or patent expirations.

Legal Proceedings

• Settlement agreements announced to resolve Biktarvy patent litigation with generic manufacturers Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd., extending U.S. exclusivity to April 1, 2036.

Stakeholder Impact

• Shareholders: Positive impact due to increased EPS, raised guidance, extended patent exclusivity for Biktarvy, and continued dividend payments ($0.79 per share declared). Moodys' positive outlook upgrade could also be favorable.
• Patients: Positive impact from the strong start of Yeztugo, growing uptake of Biktarvy, Descovy, and Livdelzi, and positive data for Trodelvy. The partnership with PEPFAR will deliver lenacapavir for HIV PrEP to up to two million people.
• Employees: Potential positive impact from the planned $32 billion investment in the U.S. through 2030, including a new Pharmaceutical Development and Manufacturing Technical Development Center, which could lead to job creation or stability.
• Competitors: The extended Biktarvy patent exclusivity could pose a challenge for generic manufacturers and other companies developing HIV treatments.
• Regulatory Authorities: Continued engagement with regulatory bodies for product approvals and clinical holds.

Next Steps

• Multiple potential product launches in 2026.
• Continued development of the clinical pipeline, including ongoing trials for Trodelvy, domvanalimab, and zimberelimab.
• Further commercialization and access strategy management for lenacapavir for HIV PrEP.
• Investment in a new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City, California, as part of a planned $32 billion investment in the U.S. through 2030.
• Future dividends will be subject to Board approval.

Key Dates

Recommendation

The filing presents a highly positive outlook for Gilead. The significant increase in diluted EPS, driven by strong core product performance (excluding Veklury) and the non-recurrence of a major impairment charge, demonstrates robust profitability. The most impactful news is the extension of Biktarvy's U.S. patent exclusivity to 2036, securing a critical revenue stream for an additional two years beyond previous expectations. This provides long-term revenue visibility and reduces patent cliff concerns. The raised full-year guidance, strong pipeline momentum, positive data for Trodelvy, and strategic investments further reinforce a strong growth trajectory. Despite some headwinds in Cell Therapy, the overall picture suggests a company well-positioned for sustained growth and shareholder value creation, making it a strong buy for long-term investors.

Keywords

Gilead Sciences, GILD, Q3 2025 Earnings, Financial Results, HIV, Biktarvy, Descovy, Veklury, Cell Therapy, Oncology, Trodelvy, Livdelzi, Pharmaceutical, Biotechnology, SEC Filing, 8-K, Patent Litigation, Lenacapavir, Yeztugo, PrEP, Interius BioTherapeutics, Moodys Rating